Q: What is Jaythari used for?

Jaythari is used to treat Duchenne muscular dystrophy (patients ≥5 years).

Q: How does Jaythari work?

Mechanism of Action Jaythari is a type of medicine known as a kinase inhibitor. It works by interfering with the activity of specific proteins that help tumor cells grow and survive. Its primary target is a protein called colony-stimulating factor 1 receptor (CSF1R). In conditions like tenosynovial giant cell tumor (TGCT), the body produces an excess of signals that activate these receptors. When these receptors are triggered, they tell cells to multiply rapidly, leading to the formation of a tumor. Jaythari binds to these receptors and blocks the signals, which helps to: Slow down or stop the growth of the tumor. Interrupt the processes that allow these specific tumor cells to survive. In addition to CSF1R, Jaythari also inhibits other similar proteins, such as KIT and FLT3, which are involved in cell signaling and growth pathways.

Q: What are the active ingredients in Jaythari?

The active ingredient in Jaythari is deflazacort .

Q: What are the side effects of Jaythari?

Common side effects of Jaythari may include Not FDA approved . No reliable, publicly available data defining common side effects. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Jaythari?

Jaythari belongs to the biguanide drug class.

Q: What is the dosage of Jaythari and how do I take it?

How to Take Jaythari Jaythari should be taken exactly as directed by your healthcare provider. It is typically taken once a day at the same time each day. The tablets must be swallowed whole with water. Do not crush, chew, or break the tablets. Breaking the tablets can cause the medication to be absorbed too quickly, which may increase the risk of side effects. Food and Drink Considerations Take Jaythari on an empty stomach. This means taking it at least one hour before eating or at least two hours after a meal. Avoid eating grapefruit or drinking grapefruit juice while using this medication, as it can interfere with how the drug works in your body. Missed Dose If you miss a dose, take it as soon as you remember. However, if your next dose is due in less than twelve hours, skip the missed dose and return to your regular schedule. Do not take two doses at the same time to make up for a missed one.

Q: Is Jaythari safe during pregnancy and breastfeeding?

Pregnancy Based on its mechanism of action and findings from animal studies, Jaythari can cause harm to an unborn baby if taken during pregnancy. There is currently no data on the use of this medication in pregnant women to inform a drug-associated risk of major birth defects or miscarriage. If you are pregnant or planning to become pregnant, discuss the potential risks with your healthcare provider. Females who are able to become pregnant should have a pregnancy test before starting treatment to ensure they are not pregnant. Contraception Females: Use effective contraception during treatment with Jaythari and for 1 month after the final dose. Males: If you have a female partner who can become pregnant, use effective contraception during treatment and for 1 week after the final dose. Breastfeeding It is not known if Jaythari passes into human breast milk or how it might affect a nursing child or milk production. Due to the potential for serious side effects in a breastfed infant, it is advised that you do not breastfeed during treatment and for at least 1 week after the last dose.

Q: What is the FDA approval status of Jaythari?

FDA Approval Status Jaythari is an FDA-approved prescription medication containing the active ingredient azathioprine. It belongs to a class of drugs known as immunosuppressive antimetabolites. Approved Indications The FDA has approved Jaythari for the following specific uses: Kidney Transplantation: It is indicated as an adjunct for the prevention of rejection in renal homotransplantation. Rheumatoid Arthritis: It is indicated for the treatment of active, severe rheumatoid arthritis in adults to reduce signs and symptoms when the disease has not responded to conventional treatments like rest, nonsteroidal anti-inflammatory drugs (NSAIDs), or other disease-modifying antirheumatic drugs (DMARDs). Boxed Warning Jaythari carries a Boxed Warning because chronic immunosuppression with azathioprine increases the risk of developing malignancies (cancers) in humans. These risks include: Lymphoma: Increased reports of post-transplant lymphomas. Hepatosplenic T-cell Lymphoma (HSTCL): Reports of this rare and often fatal cancer have occurred, primarily in patients with inflammatory bowel disease, although Jaythari is not specifically FDA-approved for that condition. Skin Cancer: Patients are advised to limit exposure to sunlight and ultraviolet (UV) light while taking this medication. Regulatory Monitoring Due to the risk of severe bone marrow suppression, the FDA-approved labeling requires frequent complete blood count (CBC) monitoring, including platelets, for patients receiving this therapy.

Question 1

What is Jaythari?

Accepted Answer

Jaythari is a medication that works by suppressing the immune system. It is classified as an immunosuppressive antimetabolite because it interferes with the production of certain genetic materials needed for cells to grow and multiply.

By limiting the growth of these cells, the medication helps to decrease the body's overall immune response.

Question 2

What is Jaythari used for?

Accepted Answer

Jaythari is used to treat Duchenne muscular dystrophy (patients ≥5 years).

Question 3

How does Jaythari work?

Accepted Answer

Mechanism of Action

Jaythari is a type of medicine known as a kinase inhibitor. It works by interfering with the activity of specific proteins that help tumor cells grow and survive. Its primary target is a protein called colony-stimulating factor 1 receptor (CSF1R).

In conditions like tenosynovial giant cell tumor (TGCT), the body produces an excess of signals that activate these receptors. When these receptors are triggered, they tell cells to multiply rapidly, leading to the formation of a tumor. Jaythari binds to these receptors and blocks the signals, which helps to:

Slow down or stop the growth of the tumor.
Interrupt the processes that allow these specific tumor cells to survive.

In addition to CSF1R, Jaythari also inhibits other similar proteins, such as KIT and FLT3, which are involved in cell signaling and growth pathways.

Question 4

What are the active ingredients in Jaythari?

Accepted Answer

The active ingredient in Jaythari is deflazacort.

Question 5

What are the side effects of Jaythari?

Accepted Answer

Common side effects of Jaythari may include Not FDA approved. No reliable, publicly available data defining common side effects.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Jaythari?

Accepted Answer

Jaythari belongs to the biguanide drug class.

Question 7

What is the dosage of Jaythari and how do I take it?

Accepted Answer

How to Take Jaythari

Jaythari should be taken exactly as directed by your healthcare provider. It is typically taken once a day at the same time each day.

The tablets must be swallowed whole with water. Do not crush, chew, or break the tablets. Breaking the tablets can cause the medication to be absorbed too quickly, which may increase the risk of side effects.

Food and Drink Considerations

Take Jaythari on an empty stomach. This means taking it at least one hour before eating or at least two hours after a meal.
Avoid eating grapefruit or drinking grapefruit juice while using this medication, as it can interfere with how the drug works in your body.

Missed Dose

If you miss a dose, take it as soon as you remember. However, if your next dose is due in less than twelve hours, skip the missed dose and return to your regular schedule. Do not take two doses at the same time to make up for a missed one.

Question 8

Is Jaythari safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Based on its mechanism of action and findings from animal studies, Jaythari can cause harm to an unborn baby if taken during pregnancy. There is currently no data on the use of this medication in pregnant women to inform a drug-associated risk of major birth defects or miscarriage.

If you are pregnant or planning to become pregnant, discuss the potential risks with your healthcare provider. Females who are able to become pregnant should have a pregnancy test before starting treatment to ensure they are not pregnant.

Contraception

Females: Use effective contraception during treatment with Jaythari and for 1 month after the final dose.
Males: If you have a female partner who can become pregnant, use effective contraception during treatment and for 1 week after the final dose.

Breastfeeding

It is not known if Jaythari passes into human breast milk or how it might affect a nursing child or milk production. Due to the potential for serious side effects in a breastfed infant, it is advised that you do not breastfeed during treatment and for at least 1 week after the last dose.

Question 9

What forms and strengths does Jaythari come in?

Accepted Answer

Jaythari is supplied as a film-coated tablet for oral administration. The tablets are scored, which allows them to be divided into equal portions if necessary.

Question 10

What is the FDA approval status of Jaythari?

Accepted Answer

FDA Approval Status

Jaythari is an FDA-approved prescription medication containing the active ingredient azathioprine. It belongs to a class of drugs known as immunosuppressive antimetabolites.

Approved Indications

The FDA has approved Jaythari for the following specific uses:

Kidney Transplantation: It is indicated as an adjunct for the prevention of rejection in renal homotransplantation.
Rheumatoid Arthritis: It is indicated for the treatment of active, severe rheumatoid arthritis in adults to reduce signs and symptoms when the disease has not responded to conventional treatments like rest, nonsteroidal anti-inflammatory drugs (NSAIDs), or other disease-modifying antirheumatic drugs (DMARDs).

Boxed Warning

Jaythari carries a Boxed Warning because chronic immunosuppression with azathioprine increases the risk of developing malignancies (cancers) in humans. These risks include:

Lymphoma: Increased reports of post-transplant lymphomas.
Hepatosplenic T-cell Lymphoma (HSTCL): Reports of this rare and often fatal cancer have occurred, primarily in patients with inflammatory bowel disease, although Jaythari is not specifically FDA-approved for that condition.
Skin Cancer: Patients are advised to limit exposure to sunlight and ultraviolet (UV) light while taking this medication.

Regulatory Monitoring

Due to the risk of severe bone marrow suppression, the FDA-approved labeling requires frequent complete blood count (CBC) monitoring, including platelets, for patients receiving this therapy.

Question 11

What should I know about Jaythari and withdrawal?

Accepted Answer

Jaythari is an immunosuppressant used to manage long-term conditions. Stopping this medication without medical supervision can lead to significant health risks depending on the condition being treated:

Organ Rejection: For patients who have received a kidney transplant, Jaythari helps prevent the immune system from attacking the new organ. Discontinuing the drug can lead to transplant rejection.
Disease Flare-ups: In patients with rheumatoid arthritis, stopping the medication may cause a recurrence of symptoms such as joint pain, inflammation, and reduced mobility.

It is important to continue taking Jaythari exactly as prescribed. If you experience side effects or have concerns about the medication, speak with a healthcare provider before making any changes to your treatment plan.

Jaythari

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Jaythari

Hospitals.net Disclosure